Anti-S100A4 Antibody
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, IF, FC |
---|---|
Primary Accession | P26447 |
Other Accession | 654444 |
Reactivity | Human, Mouse |
Host | Mouse |
Clonality | Monoclonal |
Isotype | Mouse / IgG1, kappa |
Clone Names | S100A4/1481 |
Calculated MW | 11729 Da |
Gene ID | 6275 |
---|---|
Other Names | S100A4; S100 calcium-binding protein A4; Calvasculin; CAPL; Fibroblast specific protein 1 (FSP1); Leukemia multidrug resistance associated protein; Malignant transformation suppression 1 (MTS1); Metastasin; Placental calcium-binding protein |
Application Note | Flow Cytometry (0.5-1ug/million cells); Immunofluorescence (1-2ug/ml); ,Western Blotting (0.5-1ug/ml),Immunohistology (Formalin-fixed) (0.25-0.5ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined. |
Format | 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
Precautions | Anti-S100A4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | S100A4 |
---|---|
Synonyms | CAPL, MTS1 |
Function | Calcium-binding protein that plays a role in various cellular processes including motility, angiogenesis, cell differentiation, apoptosis, and autophagy (PubMed:16707441, PubMed:23752197, PubMed:30713770). Increases cell motility and invasiveness by interacting with non-muscle myosin heavy chain (NMMHC) IIA/MYH9 (PubMed:16707441). Mechanistically, promotes filament depolymerization and increases the amount of soluble myosin-IIA, resulting in the formation of stable protrusions facilitating chemotaxis (By similarity). Modulates also the pro-apoptotic function of TP53 by binding to its C-terminal transactivation domain within the nucleus and reducing its protein levels (PubMed:23752197). Within the extracellular space, stimulates cytokine production including granulocyte colony- stimulating factor and CCL24 from T-lymphocytes (By similarity). In addition, stimulates T-lymphocyte chemotaxis by acting as a chemoattractant complex with PGLYRP1 that promotes lymphocyte migration via CCR5 and CXCR3 receptors (PubMed:26654597, PubMed:30713770). |
Cellular Location | Secreted. Nucleus Cytoplasm {ECO:0000250|UniProtKB:P07091} |
Tissue Location | Ubiquitously expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
S100A4 belongs to the S100 super-family of proteins containing 2 EF-hand calcium-binding domains. S100 genes include at least 25 members, including S100A1-S100A18, trichohyalin, filaggrin, repetin, S100P, and S100Z. S100A4 exerts its function via direct interaction with a number of proteins including P53, P63, non-muscle myosin IIA, α6β4 integrin, and liprin b1. S100A4 is overexpressed in highly metastatic cancers, which makes it useful as a marker of tumor progression.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.